Mitsubishi Tanabe Pharma America announces FDA acceptance of new drug application for oral edaravone formulation for the treatment of ALS

Mitsubishi Tanabe Pharma

12 January 2022 - Mitsubishi Tanabe Pharma America today announced the U.S. FDA has accepted the new drug application for an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis. 

The FDA has accepted the application for priority review with a Prescription Drug User Fee Act action date of 12 May 2022.

Read Mitsubishi Tanabe Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier